Baicheng Pharmaceutical announced on the evening of January 7 that Baicheng Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, recently received a clinical trial approval notice from the State Drug Administration. The HQ2303 drug independently developed by the company will carry out clinical trial research. The HQ2303 is indicated for the treatment of essential hypertension. Currently, no product has been approved for marketing at home or abroad.

Zhitongcaijing · 01/07 08:49
Baicheng Pharmaceutical announced on the evening of January 7 that Baicheng Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, recently received a clinical trial approval notice from the State Drug Administration. The HQ2303 drug independently developed by the company will carry out clinical trial research. The HQ2303 is indicated for the treatment of essential hypertension. Currently, no product has been approved for marketing at home or abroad.